预约演示
更新于：2025-07-19
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2025-07-19
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
21
项与 磷酸钠倍他米松 相关的临床试验ISRCTN38950110
Comparison of the analgesic non-inferiority of ultrasound-guided injections of ACS (Orthokine) into the cervical fascial planes versus application along the cervical facet joints in patients with neck pain: A randomized, open-label, controlled clinical trial. (Protocol).
NCT05571046
Efficacy of Intramuscular Glucocorticoid Injection in Patients With Lumbar Radicular Pain
NCT04153396
Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE)
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
1,240
项与 磷酸钠倍他米松 相关的文献（医药）2025-09-01EARLY HUMAN DEVELOPMENT
Antenatal corticosteroid exposure and neonatal outcomes in term infants
Article
作者: Chung, Hao-Wei ; Liang, Fu-Wen ; Yu, Chia-Hung ; Huang, Chiao-Yun
BACKGROUND:
Antenatal corticosteroids (ACS) are widely used to mitigate respiratory distress in preterm infants. Although the benefits of ACS in preterm births are well established, less is known about the short-term neonatal risks when ACS is administered during pregnancies that result in term delivery. Additionally, the impact of gestational age at the time of ACS exposure in this population remains unclear.
AIM:
To evaluate the association between ACS exposure and short-term neonatal outcomes in term-born singleton infants, and further assess outcome variation by gestational age at exposure.
METHOD:
This retrospective, population-based cohort study used data from the Taiwan Maternal and Child Health Database and the National Health Insurance Research Database to compare term-born singleton infants exposed to ACS for threatened preterm labor with those unexposed, whose mothers had no diagnosis of preterm labor and no recorded ACS administration. Neonatal outcomes were analyzed using multivariable logistic regression.
RESULTS:
Among 800,024 term births, 5577 (0.6 %) were exposed to ACS due to preterm labor. ACS-exposed infants had higher rates of SGA, CPAP, oxygen use, NICU admission, sepsis, hypoglycemia, TTNB, and jaundice (P < 0.001). Adjusted analyses revealed higher odds of SGA (aOR 1.30; 95 % CI 1.20-1.41), NICU admission (aOR 1.16; 95 % CI 0.99-1.36), and hyperbilirubinemia (aOR 1.49; 95 % CI 1.38-1.61) in the exposed group. Exposure between 28 and 33 weeks was associated with increased odds of oxygen therapy (aOR 1.42; 95 % CI 1.21-1.67) and TTNB (aOR 1.40; 95 % CI 1.00-1.94).
CONCLUSION:
ACS exposure is associated with increased risks of short-term neonatal complications among term-born infants, especially when exposure between 28 and 33 weeks' gestation. Even when pregnancies end in term delivery, ACS exposure may still increase neonatal morbidity risk.
2025-08-01American Journal of Obstetrics & Gynecology MFM
Antenatal dexamethasone vs betamethasone on glycemic control in mild gestational diabetes: a randomized clinical trial
Article
作者: Saaid, Rahmah ; Hong, Jesrine ; Shareef, Fathimath Shamaa ; Omar, Siti Zawiah ; Tan, Peng Chiong ; Hamdan, Mukhri
BACKGROUND:
Preterm birth and gestational diabetes mellitus are common complications of pregnancy. A widely known side effect of antenatal corticosteroids on fetal maturity in preterm births is maternal hyperglycemia. The choice of antenatal corticosteroid regimens between dexamethasone and betamethasone highly depends on local availability and cost, as current but inconclusive evidence shows similar neonatal outcomes for both regimes.
OBJECTIVE:
This study aimed to compare four 6.0-mg doses of antenatal dexamethasone administered 12 hours apart vs two 11.4-mg doses of antenatal betamethasone administered 24 hours apart in medical nutrition therapy-controlled gestational diabetes mellitus cases on maternal glycemic response for up to 3 consecutive days after administration.
STUDY DESIGN:
This was a randomized controlled clinical trial conducted between February 2021 and August 2023 at a tertiary university hospital in Malaysia. Pregnant participants with diet-controlled gestational diabetes mellitus and prescribed antenatal corticosteroid were randomized to either four 6.0-mg doses of dexamethasone administered 12 hours apart or two 11.4-mg doses of betamethasone administered 24 hours apart. Self-monitoring of capillary blood glucose level (6 points per 24 hours: 2 hours before and after a meal for the 3 main meals) was started after the first dose of allocated antenatal corticosteroid. Hyperglycemia was defined as a fasting or premeal glucose level of ≥5.3 mmol/L (≤95 mg/dL) or a 2-hour postmeal glucose level of ≥6.7 mmol/L (120 mg/dL). The primary outcomes were number of hyperglycemic episodes within the first and second 24 hours after antenatal corticosteroid administration. Analyses were performed using the t test, Mann-Whitney U test, and chi-square test, as appropriate.
RESULTS:
The median hyperglycemic episodes were similar between the dexamethasone group and the betamethasone group: 4.0 (interquartile range, 2.3-5.0) vs 4.0 (interquartile range, 3.5-5.0), respectively, on day 1 (P=.168), 4.0 (interquartile range, 3.0-5.0) vs 5.0 (interquartile range, 4.0-5.0), respectively, on day 2 (P=.002), and 1.0 (interquartile range, 0.0-2.0) vs 2.0 (interquartile range, 1.0-3.0), respectively, on day 3 (P<.001). In addition, the median blood glucose levels were significantly lower in the dexamethasone group than in the betamethasone group on days 1, 2, and 3 (day 1: 6.3 [interquartile range, 5.8-7.0] vs 6.7 [interquartile range, 6.3-7.0], respectively; P=.016; day 2: 6.4 [interquartile range, 6.0-6.9] vs 6.7 [interquartile range, 6.3-7.2], respectively; P=.001; day 3: 5.2 [interquartile range, 4.8-5.5] vs 5.7 [interquartile range, 5.4-6.0], respectively; P<.001). The mean blood glucose levels were higher in the betamethasone group than in the dexamethasone group on day 1 to 3 (6.2 mmol/L [97.5% confidence interval, 6.0-6.4] vs 6.6 mmol/L [97.5% confidence interval, 6.4-6.7], respectively; mean difference, -0.374 [97.5% confidence interval, -0.521 to -0.226], respectively; P<.001). Other maternal and neonatal outcomes were not significantly different between the groups.
CONCLUSION:
In gestational diabetes mellitus on medical nutrition therapy, dexamethasone antenatal corticosteroid therapy could be preferred over betamethasone, as hyperglycemic episodes on days 2 and 3 after treatments were fewer and the median blood glucose levels were lower on day 1 to day 3.
2025-07-01JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
Antenatal corticosteroid treatment for women with hypertensive disorders of pregnancy: A population‐based study in Japan
Article
作者: Imai, Kenji ; Tano, Sho ; Kotani, Tomomi ; Katsuki, Satoru ; Fuma, Kazuya ; Matsuo, Seiko ; Kajiyama, Hiroaki ; Ushida, Takafumi
Abstract:
Aim:
This study aimed to evaluate the current antenatal corticosteroid (ACS) treatment practices for hypertensive disorders of pregnancy (HDP) in Japan, by evaluating annual trends and identifying clinical disparities and factors influencing non‐administration of ACS.
Methods:
This retrospective population‐based study was conducted using the Japanese Perinatal Research Network Database from 2013 to 2022. We analyzed ACS administration rates over time, across facility types, and the timing of delivery. Factors influencing non‐administration were identified using univariate and multivariate logistic regression analyses.
Results:
ACS administration rates among patients with HDP nearly doubled over the past decade, reaching 64.0% in 2022. Approximately 70% of patients with HDP who received ACS delivered before 34 weeks of gestation; however, only 30% achieved the optimal administration‐to‐birth interval of 48 h to 7 days. ACS administration rates in patients with HDP differed by facility type: 67.8% (1641/2419) in general perinatal medical centers, 60.5% (1107/1830) in regional perinatal medical centers, and 39.7% (23/58) in non‐perinatal medical centers. Factors contributing to non‐administration included smoking during pregnancy, eclampsia, placental abruption, HELLP syndrome, regional perinatal medical centers, non‐perinatal medical centers, and gestational hypertension. Conversely, conditions such as fetal growth restriction, threatened preterm labor, and preterm premature rupture of membranes were associated with higher rates of ACS administration.
Conclusions:
Although ACS administration rates in patients with HDP have improved over time, challenges remain in achieving optimal administration timing and addressing facility‐based disparities. To improve administration rates, clinicians should increase awareness of ACS treatment and proactively manage HDP‐related emergencies.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 139 | (SURF-200 (0.02% Betamethasone Sodium Phosphate in Vehicle)) | 壓積夢廠繭積憲構願選 = 鑰繭遞鏇蓋糧窪糧鏇襯 鏇鏇齋網願襯積簾艱繭 (窪願淵製糧鏇獵範製觸, 膚網醖選簾製憲鹽夢範 ~ 鹽製餘憲醖鹹窪衊膚鏇) 更多 | - | 2025-06-04 | ||
(SURF-200 (0.04% Betamethasone Sodium Phosphate in Vehicle)) | 壓積夢廠繭積憲構願選 = 網窪遞壓鑰蓋構顧壓鏇 鏇鏇齋網願襯積簾艱繭 (窪願淵製糧鏇獵範製觸, 窪網網築繭衊蓋淵築餘 ~ 鑰糧夢簾築鬱構製遞壓) 更多 | ||||||
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 願窪鏇築築廠鑰衊構範(襯獵襯夢範鹽糧鹽繭膚) = 餘壓願願構積顧選積築 簾遞鹽觸鹽餘積觸範觸 (鹽築膚願衊觸餘顧蓋選, 鏇積齋醖糧襯觸鏇夢憲 ~ 製觸鑰願廠夢蓋憲餘糧) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 願窪鏇築築廠鑰衊構範(襯獵襯夢範鹽糧鹽繭膚) = 衊餘願積夢網襯範構築 簾遞鹽觸鹽餘積觸範觸 (鹽築膚願衊觸餘顧蓋選, 顧製憲淵鏇鑰齋蓋鬱衊 ~ 窪選範構蓋糧艱窪糧築) 更多 | ||||||
N/A | 糖尿病 blood glucose levels | 5 | 鬱夢憲顧夢築膚壓艱網(簾顧襯衊鹹蓋製構醖選) = 獵淵餘壓齋鹽衊齋蓋願 繭憲齋窪衊繭鬱繭憲廠 (齋淵夢遞鏇齋獵壓繭獵 ) | 积极 | 2009-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用